← All trials
NCT05058352
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Apr 30, 2023
- First posted
- Sep 27, 2021
- Last posted
- Sep 27, 2021
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang Hisun Pharmaceutical Co. Ltd.Lead sponsor
- Shandong UniversityOverall official - principal investigator
- Henan Provincial Cancer HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.